Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Plan B launches “strong”

This article was originally published in The Tan Sheet

Executive Summary

Barr Pharmaceuticals says "strong sales" of Plan B emergency contraceptive following its November launch contributed to a 22% increase in sales of the firm's proprietary products during its fiscal 2007 second quarter. In a Feb. 28 earnings call, the company said proprietary product sales for the October-December period increased $17 million from the year-ago period to $98 million. The firm declined to provide Plan B sales details, but Chairman and CEO Bruce Downey said the product "is up substantially ... year over year as a result of the OTC switch." Downey said Barr's three-year exclusivity for Plan B began with its launch, but the firm is "evaluating the options that we have for protecting that franchise beyond" its patents (1"The Tan Sheet," Nov. 13, 2006, p. 8)...

You may also be interested in...

Plan B Ruling: Little Commercial Impact, Big Policy Implications

The court ruling overturning FDA's restricted distribution of the emergency contraceptive Plan B could have a number of implications for the biopharma industry - ranging from a near-term impact on confirmation of Obama administration nominees to a longer-term curbing of creative product risk management activities

Sales & Earnings In Brief

Barr: Emergency contraceptive Plan B second quarter sales increased $12 mil. over the year-ago quarter due to the OTC launch in November 2006, Barr reports in an Aug. 8 analysts call ("1The Tan Sheet" March 5, 2007, In Brief and 2"The Tan Sheet" Nov. 13 2006, p. 8). The firm's total revenues for the quarter were $637 mil., up 81% from the same period in the prior year. With Plan B boosting its proprietary division sales, generic oral contraception sales also drove overall revenue. Integration of Croatian firm PLIVA acquired in 2006 is on track, the firm reports...

Dual Package Plan B Hits Shelves Mid-November With Three-Year Exclusivity

The first product to be approved in a single package for both Rx and OTC sale - Barr Pharmaceuticals' emergency contraceptive Plan B - will be available behind pharmacy counters by mid-November, according to the firm





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts